Novo Nordisk raises sales and operating profit outlook for 2020

Bagsværd, Denmark, 8 October 2020 – Novo Nordisk today announced that the full-year sales and operating profit outlook at constant exchange rates (CER) has been raised.
In the third quarter of 2020, Novo Nordisk’s sales increased by 7% and operating profit increased by 7%, both at CER. This reflects lower than anticipated negative impacts from COVID-19 as well as underlying market demand. Sales growth was positively impacted by inventory changes at wholesaler level in the US.Following lower than anticipated negative COVID-19 impacts and underlying market demand, full-year outlook is increased for sales and operating profit, both at CER.Novo Nordisk’s full disclosure of the financial results for the first nine months of 2020 will be published on 30 October 2020.The outlook is based on a number of assumptions related to the severity and duration of impacts from COVID-19. In addition, the above expectations are based on assumptions which are further described on pages 15 and 16 of the Financial Report for the period 1 January 2020 to 30 June 2020 (Company Announcement No 49 / 2020) including that the global or regional macroeconomic and political environment will not significantly change business conditions for Novo Nordisk during the remainder of 2020.The forward-looking statements on page 21 of the Financial Report for the period 1 January 2020 to 30 June 2020 (Company Announcement No 49 / 2020) also apply to this company announcement.Conference call to be held on 9 October 2020 at 08.30 CEST